The demand for CAR T doses will increase in the coming years, rising from tens of thousands to hundreds of thousands :
- Earlier Prescription of CAR-T therapies for Leukemia and Lymphoma
- Introduction of CAR-T therapies for Autoimmune Diseases
- First CAR-T Therapies for Solid Tumors
Manufacturers will face an unprecedented industrial challenge in the pharmaceutical sector: producing large quantities of personalized CAR-T cells—some in high volumes for CAR-T therapies with multiple indications, others in smaller quantities for rare diseases.
To meet these needs, we have developed our CosyNest System
The CosyNest System
Compact & scalable
1, 5, 10 or 15 CosyNest reactors can be racked in scalable racks 6000 doses for 60m².
Closed system
Thanks to patented permeable bag culture containing all necessary reagents on Day0. Clear your cleanrooms.
Monitoring
Thanks to our patented algorithm, the number of cells is known at all times by direct observation in the bags. No sampling required.
Load & run
Pre-filled pods can be connected to the culture bag on D0 using a patented heat-sealed connection system. Save your time.
Total traceability
Thanks to RFID labelling of raw material.
Connectivity
Control software for patient data retrieval.
Configuration
Labo ‘in-house’
Préclinical and Clinical trials, small volume production in hospital laboratory.
Need : 10 to 100 CAR T/year
High intensity
CDMO, Biotech
Need : 1,000 to 30,000 CAR T/year
